AR107108A1 - Formulación inyectable de una lactona macrocíclica y levamisol - Google Patents
Formulación inyectable de una lactona macrocíclica y levamisolInfo
- Publication number
- AR107108A1 AR107108A1 ARP160103960A ARP160103960A AR107108A1 AR 107108 A1 AR107108 A1 AR 107108A1 AR P160103960 A ARP160103960 A AR P160103960A AR P160103960 A ARP160103960 A AR P160103960A AR 107108 A1 AR107108 A1 AR 107108A1
- Authority
- AR
- Argentina
- Prior art keywords
- macrocyclic lactone
- levamisole
- formulation
- triacetin
- particle size
- Prior art date
Links
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 title abstract 7
- 229960001614 levamisole Drugs 0.000 title abstract 7
- 150000002596 lactones Chemical class 0.000 title abstract 6
- 239000007972 injectable composition Substances 0.000 title 1
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 abstract 8
- 239000000203 mixture Substances 0.000 abstract 6
- 238000009472 formulation Methods 0.000 abstract 5
- 235000013773 glyceryl triacetate Nutrition 0.000 abstract 4
- 239000001087 glyceryl triacetate Substances 0.000 abstract 4
- 229960002622 triacetin Drugs 0.000 abstract 4
- 239000002245 particle Substances 0.000 abstract 3
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 abstract 2
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 abstract 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 abstract 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 abstract 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 abstract 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 abstract 2
- 229960002418 ivermectin Drugs 0.000 abstract 2
- 244000045947 parasite Species 0.000 abstract 2
- 208000030852 Parasitic disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 abstract 1
- WPNHOHPRXXCPRA-TVXIRPTOSA-N eprinomectin Chemical compound O1[C@@H](C)[C@@H](NC(C)=O)[C@H](OC)C[C@@H]1O[C@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C\C=C/[C@@H]2C)\C)O[C@H]1C WPNHOHPRXXCPRA-TVXIRPTOSA-N 0.000 abstract 1
- 229960002346 eprinomectin Drugs 0.000 abstract 1
- -1 lactone compound Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- YZBLFMPOMVTDJY-CBYMMZEQSA-N moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)\C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-CBYMMZEQSA-N 0.000 abstract 1
- 229960004816 moxidectin Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Formulaciones para controlar parásitos, que comprenden una combinación de un compuesto de lactona macrocíclica y levamisol, en donde el levamisol está en forma de particulado suspendido en triacetín y tiene un tamaño de partícula eficaz promedio (D₅₀) de £ 250 mm. Reivindicación 1: Una formulación farmacéutica inyectable que comprende lactona macrocíclica y levamisol y triacetín como portador en donde la lactona macrocíclica está en la solución y el levamisol está en la suspensión y tiene un tamaño de partícula eficaz promedio (D₅₀) de £ 250 mm. Reivindicación 12: La formulación como se reivindica en la reivindicación 11, en donde el compuesto de lactona macrocíclica es eprinomectina, ivermectina o moxidectina. Reivindicación 16: La formulación de cualquiera de las reivindicaciones 1 a 15, que comprende: aproximadamente 0,5 - 10% p/v de ivermectina, aproximadamente 15 - 20% p/v de levamisol, aproximadamente 0,1 - 1% p/v de monoestearato de aluminio, aproximadamente 0,1 - 1% p/v de hidroxitolueno butilado (BHT) y, triacetín, cantidad suficiente 100% (v/v). Reivindicación 20: Un método para tratar o prevenir parasitosis provocada por parásitos internos o externos que comprende administrar a un animal que lo necesita una cantidad eficaz de la formulación de cualquiera una de las reivindicaciones 1 - 16. Reivindicación 23: Un proceso para preparar una formulación farmacéutica inyectable que comprende: a) disolver una lactona macrocíclica en triacetín; b) mezclar la solución de lactona macrocíclica con levamisol; y c) triturar la mezcla del paso b) para lograr un tamaño de partícula promedio eficaz (D₅₀ £ 250 mm).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562270721P | 2015-12-22 | 2015-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR107108A1 true AR107108A1 (es) | 2018-03-21 |
Family
ID=57629585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103960A AR107108A1 (es) | 2015-12-22 | 2016-12-21 | Formulación inyectable de una lactona macrocíclica y levamisol |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3393455B1 (es) |
| AR (1) | AR107108A1 (es) |
| AU (2) | AU2016377165B2 (es) |
| BR (1) | BR112018012886B1 (es) |
| MX (1) | MX389712B (es) |
| WO (1) | WO2017108954A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12020550555B1 (en) * | 2017-11-07 | 2024-03-06 | Intervet Int Bv | Injectable isoxazoline pharmaceutical compositions and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1375291A (zh) * | 2001-03-16 | 2002-10-23 | 王玉万 | 一种含左旋咪唑或其盐类的兽用复方注射剂 |
| NZ552040A (en) * | 2006-12-13 | 2009-04-30 | Bomac Research Ltd | Veterinary formulation comprising an anthelmintic compound and glyceryl acetate |
| NZ594610A (en) * | 2011-08-16 | 2013-03-28 | Virbac New Zealand Ltd | Injectable Anthelmintic Formulations cotaining levamisole and one or more macrocyclic lactones for controlling internal parasites in ruminants |
| WO2013043064A1 (en) * | 2011-09-23 | 2013-03-28 | Alleva Animal Health Limited | Veterinary anthelmintic delivery system |
| CN104983680A (zh) * | 2015-06-25 | 2015-10-21 | 中国科学院东北地理与农业生态研究所 | 一种羊用复方驱虫药的稳定性纳米悬浮制剂及其制备方法 |
-
2016
- 2016-12-21 AR ARP160103960A patent/AR107108A1/es active IP Right Grant
- 2016-12-21 WO PCT/EP2016/082188 patent/WO2017108954A1/en not_active Ceased
- 2016-12-21 BR BR112018012886-4A patent/BR112018012886B1/pt active IP Right Grant
- 2016-12-21 AU AU2016377165A patent/AU2016377165B2/en active Active
- 2016-12-21 EP EP16819318.3A patent/EP3393455B1/en active Active
- 2016-12-21 MX MX2018007637A patent/MX389712B/es unknown
-
2022
- 2022-11-11 AU AU2022268378A patent/AU2022268378A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018007637A (es) | 2018-09-21 |
| MX389712B (es) | 2025-03-20 |
| WO2017108954A1 (en) | 2017-06-29 |
| AU2016377165B2 (en) | 2022-08-11 |
| AU2022268378A1 (en) | 2022-12-15 |
| NZ742888A (en) | 2024-07-26 |
| AU2016377165A1 (en) | 2018-06-14 |
| BR112018012886A2 (pt) | 2018-12-04 |
| EP3393455B1 (en) | 2021-07-21 |
| EP3393455A1 (en) | 2018-10-31 |
| BR112018012886B1 (pt) | 2024-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015003370A1 (es) | Derivados de sulfamoilpirrolamiday su uso como medicamentos para el tratamiento de la hepatitis b | |
| FI3888641T3 (fi) | Kannabidiolin käyttö Doose-oireyhtymään liittyvien kohtausten hoidossa | |
| ECSP17002135A (es) | Compuestos antiproliferativos y métodos de uso de los mismos | |
| BR112018008880A2 (pt) | composto 7-(tiazol-5-il) pirrolopirimidina como agonista de tlr7 | |
| PE20181400A1 (es) | Formulacion farmaceutica acuosa del anticuerpo anti-pd-l1 avelumab | |
| MD4584B1 (ro) | (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzil)carbamoil)-2,3,4,5,7,9,13,13a-octahidro-2,5-metanopirido[1ʹ,2ʹ:4,5]pirazino[2,1-b][1,3]oxazepin-8-olat de sodiu | |
| DOP2016000253A (es) | Nuevos compuestos | |
| UY36340A (es) | Derivados de indoles mono- o disustituidos como inhibidores de la replicación del virus del dengue | |
| MX380453B (es) | Metodo para mejorar el valor nutricional de pienso para animales. | |
| CO2020006257A2 (es) | Composiciones farmacéuticas inyectables de isoxazolina y usos de las mismas contra infestación parasitaria | |
| BR112017014683A2 (pt) | inibidor de patógenos melhorado | |
| DOP2016000007A (es) | Pirazolpiridinas sustituidas | |
| CL2016001094A1 (es) | Silicato de zirconio microporoso para el tratamiento de hipercalemia. | |
| WO2016044839A3 (en) | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds | |
| EA201700019A1 (ru) | Высокочистый оритаванцин и способ его получения | |
| MX2019004830A (es) | Composiciones farmaceuticas y usos de ellas. | |
| DOP2016000251A (es) | Inhibidores de las vías de señalización de wnt | |
| AR107108A1 (es) | Formulación inyectable de una lactona macrocíclica y levamisol | |
| AR081970A1 (es) | Formulacion inyectable de una lactona macrociclica y levamisol, formulacion y uso veterinario | |
| MX2018005730A (es) | Color derivado de caramelo con brillantez incrementada. | |
| PE20180488A1 (es) | Composiciones farmaceuticas solidas para el tratamiento del vhc | |
| MX2017013633A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas. | |
| CL2017001680A1 (es) | Composición farmacéutica para el tratamiento de enfermedades gastrointestinales | |
| CL2017000026A1 (es) | Formas de dosificación farmacéutica | |
| AR094882A1 (es) | Selamectina para el tratamiento de las infestaciones por piojos de mar, composición |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |